Advertisement

Preclinical development of a therapeutic antibody for the treatment of epithelial ovarian carcinoma

      Background: Despite active research in ovarian cancer immunotherapy, standard of care for ovarian cancer remains surgery and (neo)adjuvant chemotherapy. Patients often develop secondary resistance to chemotherapy, leading to recurrence. Since most mouse models have had a poor translational efficiency so far, there is a need for new therapy development strategies. We here present a mostly human-based pipeline that we have used for target identification and drug development and testing.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect